➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Medtronic
Johnson and Johnson
Baxter
McKinsey

Last Updated: January 27, 2021

DrugPatentWatch Database Preview

BIOTHRAX Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for BIOTHRAX

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Rho, Inc.Phase 2
Biomedical Advanced Research and Development AuthorityPhase 2
Department of Health and Human ServicesPhase 2

See all BIOTHRAX clinical trials

Recent Litigation for BIOTHRAX

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
MEDIZONE INTERNATIONAL, INC.2018-05-08
XtraLight Manufacturing, Ltd.2018-04-11
NYU Winthrop Hospital v. Microbion Corporation2017-10-20

See all BIOTHRAX litigation

PTAB Litigation
PetitionerDate
2018-07-27

See all BIOTHRAX litigation

Patent Text Search: US Patents for BIOTHRAX

These patents were identified by searching patent claims

Supplementary Protection Certificates for BIOTHRAX

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2019/013 Ireland   Start Trial PRODUCT NAME: ERAVACYCLINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; NAT REGISTRATION NO/DATE: EU/1/18/1312 20180920
1990014-1 Sweden   Start Trial PRODUCT NAME: ERAVACYCLINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/18/1312 20180924
545 Finland   Start Trial
2019C/511 Belgium   Start Trial PRODUCT NAME: ERAVACYCLINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/18/1312 20180924
122019000024 Germany   Start Trial PRODUCT NAME: ERAVACYCLINE ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/18/1312 20180920
CA 2013 00057 Denmark   Start Trial PRODUCT NAME: LEVENDE MODIFICERET VACCINIA VIRUS ANKARA; REG. NO/DATE: EU/1/13/855 20130731
LUC00107 Luxembourg   Start Trial PRODUCT NAME: ERAVACYCLINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/18/1312 20180924
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
McKesson
Colorcon
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.